Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
iShares MSCI Brazil ETF USD Acc
CSBR | US
5.87
USD-0.17
-2.90%
CSBR | US
Loading StockChartView...
About iShares MSCI Brazil ETF USD Acc
Sector
Healthcare
Industry
Biotechnology
Earnings date
31/07/2024
As of date
24/04/2026
Close
5.87
Open
6.04
High
6.04
Low
5.80
Champions Oncology Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company through its Tumorgraft Technology Platform provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics a software platform and data tool that contains comprehensive information derived from research services and clinical studies and sold on an annual subscriptions basis. The company markets its products through internet word of mouth and sales force to patients and physicians. The company was formerly known as Champions Biotechnology Inc. and changed its name to Champions Oncology Inc. in April 2011. Champions Oncology Inc. was incorporated in 1985 and is headquartered in Hackensack New Jersey.
View LessCSBR | US
Risk
45.8
Sharpe
-0.43
Luna's Score
52/100
Recommendation
Hold
Luna says (CSBR | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
What's not Working
Price Below SMA10D
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
51.8%1 month
45.8%3 months
53.0%6 months
59.1%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
22.88
Price to book
6.77
Debt to equity
-21.41
Debt to assets
0.29
Ent. to EBITDA
26.26
Ent. to rev.
1.24
PEG
-
Other Fundamentals
EBITDA
-1.17M
MarketCap
79.73M
MarketCap(USD)
79.73M
Div. yield
-
Op. margin
9.45
Erngs. growth
-28.60
Rev. growth
11.90
Ret. on equity
-432.46
Short ratio
1.50
Short perc.
3.96
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.50
Range1M
0.53
Range3M
2.21
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.20
Price X volume
8.45K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 26.26 | 0.53 | Expensive |
| Ent. to Revenue | 1.24 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 6.77 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 53.02 | 72.80 | Lower Risk |
| Debt to Equity | -21.41 | -1.23 | Cheaper |
| Debt to Assets | 0.29 | 0.25 | Par |
| Market Cap | 79.73M | 3.66B | Emerging |
